乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASH: Hematology

<乌鸦传媒>Completely Oral Regimen Effective, Feasible in APL

97% of patients alive and relapse-free at 3 years

<乌鸦传媒>Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's

3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab

<乌鸦传媒>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT

Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk

<乌鸦传媒>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL

Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease

<乌鸦传媒>C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuria

Iptacopan improved hemoglobin without transfusion versus current standard of care

<乌鸦传媒>High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphoma

European trial is "practice-changing as of today," says U.S. expert

<乌鸦传媒>Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody

Most complete responses lasted 24 months or longer after limited-duration glofitamab

<乌鸦传媒>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL

Phase III study showed 58% reduction in the risk of death versus chemo alone

<乌鸦传媒>Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Aging

Data from St. Jude cohort show higher rates of neurocognitive impairment

<乌鸦传媒>Heparin Fails to Stop Miscarriages in Women With Inherited Thrombophilia

No difference in live birth rates with or without blood thinner

<乌鸦传媒>Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod

Glycoprotein receptor inhibitor produces four times as many responses as placebo

<乌鸦传媒>Black Patients Less Likely to Get Advanced Treatments for PE

Also less likely for patients on Medicare and Medicaid

<乌鸦传媒>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT

Similar outcomes if patients went directly to transplant or received intensive salvage first

<乌鸦传媒>Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma

Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients

<乌鸦传媒>Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma

Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone

<乌鸦传媒>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT

"We should eliminate these silly neutropenic diets," expert says

<乌鸦传媒>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemia

OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy

<乌鸦传媒>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLL

Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease

<乌鸦传媒>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphoma

Updated analysis confirms advantages of less aggressive approach to low-burden disease

<乌鸦传媒>Gene Therapy Resolves Severe Pain Events in Sickle Cell Disease

LentiGlobin also normalized hemoglobin and reduced hemolysis markers

<乌鸦传媒>Can Dasatinib Dose Be Halved in Low-Risk CML?

Lower dose associated with improved tolerability, similar responses in propensity score analysis

<乌鸦传媒>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCL

Patients, trial design, logistics among possible explanations for lack of EFS benefit

<乌鸦传媒>Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/B

Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors

<乌鸦传媒>R-CHOP Toppled in First-Line DLBCL Trial

Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity

<乌鸦传媒>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALL

One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate

<乌鸦传媒>尾-Thalassemia Patients Go Transfusion-Free With Gene Therapy

Treatment with beti-cel is "potentially curative" in this transfusion-dependent group

<乌鸦传媒>R2 Maintenance for Elderly MCL Patients Worth the Risk?

Longer PFS with addition of lenalidomide to rituximab, but also more toxicity

<乌鸦传媒>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Rates

Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy

<乌鸦传媒>Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphoma

Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease

<乌鸦传媒>Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myeloma

Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity

<乌鸦传媒>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphoma

Large increases in event-free survival with two CAR T-cell products in second line

<乌鸦传媒>Upfront IDH1 Inhibitor Triples Survival in Older AML

Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy

<乌鸦传媒>Non-Hodgkin Lymphoma: Bispecific Antibodies Impress in Refractory Disease

Odronextamab, epcoritamab surpass 90% response threshold in early trials

<乌鸦传媒>Chemo-Free Combo Boosts PFS in First-Line CLL

PI3K-delta-based regimen also topped chemoimmunotherapy in relapsed setting

<乌鸦传媒>Novel Agent Active in Refractory CML

Asciminib doubles molecular response versus bosutinib after two or more prior lines of therapy

<乌鸦传媒>Gene Therapy Stops Bleeding in Hemophilia

Single injection had durable effectiveness, study showed

<乌鸦传媒>Fixed-Duration Ibrutinib-Venetoclax Promising in First-Line CLL

DFS at 1 year reaches 95% in patients with undetectable MRD

<乌鸦传媒>CRISPR-Based Tx Offers Hope in Tough-to-Treat Blood Disorders

Success with investigational use of gene editing in sickle cell disease, beta-thalassemia

<乌鸦传媒>Blood Cancers and COVID-19: 'A Medically Vulnerable' Group

Patients with hematologic malignancies and SARS-CoV-2 face higher risks for infection, death

<乌鸦传媒>JAK Inhibitor Wins in Second-Line Chronic GVHD

Twice as many patients achieved a response at week 24

1